Ironwood Pharmaceuticals
Presence
Ironwood Pharmaceuticals is one of the...
Ironwood Pharmaceuticals is a company listed under the stock ticker IRWD (US).
Ironwood Pharmaceuticals has a direct presence in 2 countries.
They are in:
- Pharmaceuticals50%
- Biotechnology50%
Acquisition, funding and merger involving Ironwood Pharmaceuticals.
- Ironwood Pharmaceuticals has announced the acquisition of VectivBio (posted on May 25 2023).
Executives
View the org chart displaying its 38 main executives
Most searched biographies at Ironwood Pharmaceuticals
- Thomas McCourt, Chief Executive Officer and Director
- Julie McHugh, Chairman of the Board
- Catherine Moukheibir, Director
Create your alert
to follow the executive moves at Ironwood Pharmaceuticals.
Pharmaceuticals
Ironwood Pharmaceuticals has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
- Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
- Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
- Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
- Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
- Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
- Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
- View more press releases Close
Social media about Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Ironwood Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Thomas McCourt 
Call Ironwood Pharmaceuticals at +1 617...
